During the past decade, ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Pierre Fabre Medicament" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld" are "BRAF V600E-mutant Metastatic Colorectal Cancer" (1 trials) and "Neoplasms" (1 trials). Many other conditions were trialed in "ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld" in a lesser frequency.

Most popular intervention types in "ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Cetuximab" (2 trials), "Encorafenib" (2 trials), "Irinotecan" (2 trials), "5-FU" (1 trials) and "5-Fluorouracil" (1 trials). Other intervention names were less common.

The vast majority of trials in "ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld" are 2 trials for "All" genders.

Currently, there are NaN active trials in "ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".